Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics COVID-19 Vaccine marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
CSL achieves a global milestone as Japan approves ARCT-154, the first sa-mRNA COVID-19 vaccine, showcasing CSL's commitment to innovation, efficacy, and prolonged protection against variants. Jonathan Edelman, MD, senior VP of CSL Vaccine’s Innovation Unit, speaks with ICT.
21.12.2023 - Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying . Seite 1